Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OGX 225

Drug Profile

OGX 225

Alternative Names: OGX-225

Latest Information Update: 28 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals; OncoGenex Technologies
  • Developer OncoGenex Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Insulin-like growth factor binding protein 2 inhibitors; Insulin-like growth factor binding protein 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 23 Feb 2017 Discontinued - Preclinical for Breast cancer (Second-line therapy or greater) in Canada (unspecified route)
  • 23 Feb 2017 Discontinued - Preclinical for Prostate cancer (Second-line therapy or greater) in Canada (unspecified route)
  • 23 Feb 2017 Discontinued - Preclinical for Solid tumours in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top